TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Point Prevalent Abstinence from vaping
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With Risk Factors for Grade 4 Neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: change-from-baseline IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with Heart Failure with Preserved Ejection Fraction (HFpEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Early wound healing molecular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early gingival tissue vascularization pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Prevalence of HPV-associated high-grade anal intraepithelial neoplasia (HGAIN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevalence of premalignant lesions of the penis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevalence and incidence of human papillomavirus (HPV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Gastrointestinal intolerance leading to premature discontinuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: % of macular hole closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Tapia's syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total nasal symptom score scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Visual analogue scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the quality by life questionnaire of rhinoconjunctivitis
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Tumor regression level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in baseline intravaginal latency time (IVLT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in International Index of Erectile Dysfunction - Erectile Dysfunction domain (IIEF-EF) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean of SUVr of [18F]-DPA-714 in frontal lobes compared to cerebellar lobes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: stroke or death within 30 days
Endpoint domain: Mortality/survival
Primary endpoint: any ischemic stroke or revascularization beyond 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Change in Health Mindset
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Neutrophil Lymphocyte Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Interleukin 10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Eczema Area and Severity Index (EASI 50) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in meeting the aerobic activity goal at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Step counts at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in automated office BP (AOBP) SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Lower Urinary Tract Symptoms (LUTS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Western Ontario and McMaster (WOMAC) Universities Osteoarthritis Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Appointment attendance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Safety and tolerability of AROG4-01
Endpoint domain: Adverse events/effects
Primary endpoint: Core temperature (Peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart rate variability: RMSSD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean geometric increase of RSV-A and RSV-B neutralizing antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: REALISE score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Problematic Internet Use Scale-Adolescent (PIUS-A)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of response to stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in subjective sleep quality from first day to 3rd day of ICU recruitment
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change of subjective sleep quality from before ICU and admission for 30 and 180 days after ICU discharge
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change of objective sleep from 1st day to 3rd day of ICU recruitment
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in suicidal ideations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in antidepressant response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC 0-t of budesonide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of SpO2 Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Edinburgh Prenatal Depression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: General Self Efficacy Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in vaccine literacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Experience of older patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Coronary plaque assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Sputum eosinophilia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Post workout kidney damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Internal organ damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Daily Urination Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in physical competencies
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in cognitive competencies
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in affective competencies
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in buccolingual horizontal alveolar ridge width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success of SNM for neurogenic lower urinary tract dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Male bladder function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Female bladder function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in the pennation angle of the vastus lateralis muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in the length of the fascicle of the vastus lateralis muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in vastus lateralis muscle thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in muscle quality index (MQI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Symmetry of knee flexion/extension kinematics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Symmetry of Integrated EMG in Rectus Femoris
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Symmetry of Integrated EMG in Biceps Femoris Long Head
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Symmetry of Integrated EMG in Tibialis Anterior
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Symmetry of Integrated EMG in Medial Gastrocnemius
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Stent patency assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune Inflammation-Related Protein Complexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: treatment-related G2+ respiratory toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Sleep Spindle Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Vineland Adaptive Behavior (VABS) Socialization growth scale
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Proportion of participants achieving SRI-4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: community state type (CST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HPV VL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: PAX1 methylation test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion with PDC >=0.8 at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean difference on the Aberrant Behavior Checklist-Irritability (ABC-I) subscale total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of patients referred to PCPs for CKD screening
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: postoperative maladaptive behavior rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative change in Alopecia areata severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinician-Administered PTSD Scale for DSM-V (CAPS-5)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Coronary care unit admission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Diagnostic accuracy of polyp histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to obtain images of the heart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of participants who experience adverse events (AEs) through Week 48
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants who discontinue study intervention due to AEs through Week 48
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number and percentage of participants with adverse event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number and percentage of participants with serious adverse event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number and percentage of participants with clinically defined abnormal laboratory values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short Chain Fatty Acid (SCFA) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Valvular heart disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Flowsense Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from diagnosis to imaging modality (CEM or MRI)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time from diagnosis to first treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of patient visits generated from the imaging modality
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Alpha-diversity of Sino-nasal Microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time-in-Range (TIR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time-in-Tight Range (TITR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Metrics of Glucose Variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fraction of Dose Excreted in Urine (Feur)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Bioavailability (F) of LY3537982
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Anti-Clot treatment scale (ACTS) questionnaire results
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Parasite reduction ratio (PRR48)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Parasite Clearance Half-life (PCt1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Parasite Regrowth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Peripheral Insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Hunger
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain scores on a 0-10 visual analog scale at rest and with deep breathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total cumulative opioid consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Nerve Histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants Experiencing Treatment-emergent Adverse Events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Experiencing Treatment-emergent Serious Adverse Events (TESAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Experiencing Clinically Significant Changes in Laboratory Assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal composite adverse outcome variable
Endpoint domain: Adverse events/effects
Primary endpoint: adiographic response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathological positive rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of comfort changes (Comfort Daisies)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Level of comfort changes (Visual Analogue Scale)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Location of evoked sensory percepts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stimulation perceptual thresholds to stimulus parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stimulation neurophysiology thresholds to stimulus parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrence rate of EBD stones
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fat Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in alcohol use quantity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in alcohol use frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in AUDIT items 5 to 10 scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diversity and composition of the microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients in treatment free Remission (TFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total intraoperative crystalloid consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of severe neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Occurrence of hematological toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rose Dyspnea Scale (RDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Euro-QOL 5 Dimension Visual Analog Scale (EQ5D-VAS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Combined Assessment of ALS Functional Rating Scale-Revised (ALSFRS-R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival After 24 Weeks of Treatment
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of EGFR ex20ins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of EGFR ex20ins Subtypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Frequency of Each EGFR ex20ins Subtype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence rate of mpox infection between the immediate versus delayed vaccination groups
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of adverse events between the vaccination groups
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rate of mpox infection between the vaccinated cohort versus the unvaccinated cohort
Endpoint domain: Mortality/survival
Primary endpoint: variation in the metabolite TMA-Cho (trimethylamine-choline) before surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: variation in the metabolite TMA-Cho (trimethylamine-choline) after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cumulative toxicity signals and safety profile
Endpoint domain: Adverse events/effects
Primary endpoint: Patient experience with the consent form
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cmax of TY-9591 and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Osimertinib and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-72h) of TY-9591 and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-72h) of Osimertinib and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of product related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Level of CD200 diagnostic marker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: trauma cases
Endpoint domain: Adverse events/effects
Primary endpoint: Progression into organ dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relapse of Clostridioides difficile infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Curvature angle of the cervical spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: root-mean-square value (RMS) of Surface electromyography for both upper trapezius and levator scapula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Sensitivity of the multi-omics model
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of the multi-omics model
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue of origin accuracy of the multi-omics model
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient-reported pain levels
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: patient-reported anxiety levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in episodic memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Access circuit primary patency of AVG at 6-months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: (De)tumescence duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Menstrual regularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Occurrence of dose reduction and discontinuation of investigational medicinal product due to TEAE
Endpoint domain: Adverse events/effects
Primary endpoint: Standard uptake value ratio (SUVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BDNF levels in breastmilk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes